We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

German Prefilled Syringe Manufacturer to Double Production Capability

By LabMedica International staff writers
Posted on 19 Oct 2015
A major manufacturer of pre-filled sterile syringes, cartridges, and vials will be investing approximately EUR 300 million to expand and upgrade its manufacturing facilities over an estimated five-year period.

Vetter (Ravensburg, Germany) has stated that the expansion of its "Ravensburg Vetter West" facility was designed to meet future customer expectations and regulatory requirements at an early stage, maintaining a level of manufacturing excellence that customers have come to expect from Vetter. Structural work for the facility enlargement, which will more than double its current capacity, had been completed with the site being on schedule to become fully operational in 2017.

Image: A Vetter aseptically pre-filled syringe (Photo courtesy of Vetter).
Image: A Vetter aseptically pre-filled syringe (Photo courtesy of Vetter).

Among Vetter's many products is the patented dual-chamber syringe. A freeze-dried (lyophilized) drug resides in one chamber; liquid in the other. Pushing the plunger mixes the two, reconstituting the drug. The technology prolongs shelf-life, facilitates accurate dosing, and enables patients to self-administer.

“We are continuously monitoring and reacting to a changing marketplace and are pleased that we are in the position to be able to make these strategic investments to further develop our sites and meet these challenges. Individually and collectively, they will help us keep pace with the market and allow us to continue to build a successful future for Vetter and our customers,” said Peter Soelkner managing director of Vetter.

Related Links:

Vetter 



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Latest BioResearch News

Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns

Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma

New Method Simplifies Preparation of Tumor Genomic DNA Libraries